Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer.

de la Cueva A, Emmerling M, Lim SL, Yang S, Trackman PC, Sonenshein GE, Kirsch KH.

Carcinogenesis. 2018 Jul 3;39(7):921-930. doi: 10.1093/carcin/bgy045.

2.

UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells.

Sánchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE.

J Cell Biochem. 2017 Aug;118(8):2347-2356. doi: 10.1002/jcb.25893. Epub 2017 Apr 25.

PMID:
28106301
3.

Endogenous light scattering as an optical signature of circulating tumor cell clusters.

Lyons J, Polmear M, Mineva ND, Romagnoli M, Sonenshein GE, Georgakoudi I.

Biomed Opt Express. 2016 Feb 25;7(3):1042-50. doi: 10.1364/BOE.7.001042. eCollection 2016 Mar 1.

4.

miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.

Das SG, Romagnoli M, Mineva ND, Barillé-Nion S, Jézéquel P, Campone M, Sonenshein GE.

Breast Cancer Res. 2016 Apr 2;18(1):40. doi: 10.1186/s13058-016-0699-z.

5.

N-glycosylation regulates ADAM8 processing and activation.

Srinivasan S, Romagnoli M, Bohm A, Sonenshein GE.

J Biol Chem. 2014 Nov 28;289(48):33676-88. doi: 10.1074/jbc.M114.594242. Epub 2014 Oct 21.

6.

Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways.

Bais MV, Ozdener GB, Sonenshein GE, Trackman PC.

Oncogene. 2015 Apr 9;34(15):1928-37. doi: 10.1038/onc.2014.147. Epub 2014 Jun 2.

7.

ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.

Romagnoli M, Mineva ND, Polmear M, Conrad C, Srinivasan S, Loussouarn D, Barillé-Nion S, Georgakoudi I, Dagg Á, McDermott EW, Duffy MJ, McGowan PM, Schlomann U, Parsons M, Bartsch JW, Sonenshein GE.

EMBO Mol Med. 2014 Feb;6(2):278-94. doi: 10.1002/emmm.201303373. Epub 2013 Dec 27.

8.

Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide.

Sato S, Zhao Y, Imai M, Simister PC, Feller SM, Trackman PC, Kirsch KH, Sonenshein GE.

PLoS One. 2013 Oct 22;8(10):e77288. doi: 10.1371/journal.pone.0077288. eCollection 2013.

9.

Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells.

Mineva ND, Paulson KE, Naber SP, Yee AS, Sonenshein GE.

PLoS One. 2013 Sep 11;8(9):e73464. doi: 10.1371/journal.pone.0073464. eCollection 2013.

10.

Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5.

Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML, Sonenshein GE.

Cancer Res. 2012 Dec 1;72(23):6268-78. doi: 10.1158/0008-5472.CAN-12-2270. Epub 2012 Oct 10.

11.

Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide.

Yu Z, Sato S, Trackman PC, Kirsch KH, Sonenshein GE.

PLoS One. 2012;7(3):e33287. doi: 10.1371/journal.pone.0033287. Epub 2012 Mar 15.

12.

Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts.

Bais MV, Nugent MA, Stephens DN, Sume SS, Kirsch KH, Sonenshein GE, Trackman PC.

PLoS One. 2012;7(2):e31188. doi: 10.1371/journal.pone.0031188. Epub 2012 Feb 8.

13.

The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits β-catenin transcriptional activity in lung cancer cells.

Sánchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE.

Mol Cell Biol. 2011 Aug;31(16):3286-97. doi: 10.1128/MCB.01426-10. Epub 2011 Jun 20.

14.

The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.

Sato S, Trackman PC, Mäki JM, Myllyharju J, Kirsch KH, Sonenshein GE.

Mol Cell Biol. 2011 Jul;31(13):2683-95. doi: 10.1128/MCB.01148-10. Epub 2011 May 2.

15.

Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis.

Min C, Zhao Y, Romagnoli M, Trackman PC, Sonenshein GE, Kirsch KH.

J Cell Biochem. 2010 Dec 1;111(5):1160-8. doi: 10.1002/jcb.22828.

16.

Characterization of recombinant lysyl oxidase propeptide.

Vora SR, Guo Y, Stephens DN, Salih E, Vu ED, Kirsch KH, Sonenshein GE, Trackman PC.

Biochemistry. 2010 Apr 6;49(13):2962-72. doi: 10.1021/bi902218p.

17.

TAp63 is a transcriptional target of NF-kappaB.

Wu J, Bergholz J, Lu J, Sonenshein GE, Xiao ZX.

J Cell Biochem. 2010 Mar 1;109(4):702-10. doi: 10.1002/jcb.22449.

18.

A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.

Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE.

Cancer Res. 2009 Aug 15;69(16):6685-93. doi: 10.1158/0008-5472.CAN-08-4818. Epub 2009 Aug 4.

19.

Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.

Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, Trackman PC.

Oncogene. 2009 Sep 24;28(38):3390-400. doi: 10.1038/onc.2009.203. Epub 2009 Jul 13.

20.

RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1.

Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, Chalbos D, Sonenshein GE.

Mol Cell Biol. 2009 Jul;29(14):3832-44. doi: 10.1128/MCB.00032-09. Epub 2009 May 11.

21.

Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer.

Dominguez I, Sonenshein GE, Seldin DC.

Cell Mol Life Sci. 2009 Jun;66(11-12):1850-7. doi: 10.1007/s00018-009-9153-z. Review.

22.

Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation.

Mineva ND, Wang X, Yang S, Ying H, Xiao ZX, Holick MF, Sonenshein GE.

J Cell Physiol. 2009 Sep;220(3):593-9. doi: 10.1002/jcp.21765.

23.

The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells.

Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, Kirsch KH.

J Biol Chem. 2009 Jan 16;284(3):1385-93. doi: 10.1074/jbc.M802612200. Epub 2008 Nov 21.

24.

c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.

Chandramohan V, Mineva ND, Burke B, Jeay S, Wu M, Shen J, Yang W, Hann SR, Sonenshein GE.

J Cell Biochem. 2008 Aug 15;104(6):2091-106. doi: 10.1002/jcb.21765.

PMID:
18393360
25.

NF-kappaB and epithelial to mesenchymal transition of cancer.

Min C, Eddy SF, Sherr DH, Sonenshein GE.

J Cell Biochem. 2008 Jun 1;104(3):733-44. doi: 10.1002/jcb.21695. Review.

PMID:
18253935
26.

Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype.

Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH, Sonenshein GE.

Cancer Res. 2007 Dec 15;67(24):11742-50.

27.

Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue.

Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH.

J Cell Biochem. 2008 May 15;104(2):402-17.

PMID:
18059014
28.
29.

Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.

Eddy SF, Kane SE, Sonenshein GE.

Cancer Res. 2007 Oct 1;67(19):9018-23.

30.
32.

CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis.

Mineva ND, Rothstein TL, Meyers JA, Lerner A, Sonenshein GE.

J Biol Chem. 2007 Jun 15;282(24):17475-85. Epub 2007 Apr 19.

33.

Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.

Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE.

Nat Cell Biol. 2007 Apr;9(4):470-8. Epub 2007 Mar 18.

34.

The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer.

Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, Sonenshein GE.

Cancer Res. 2007 Feb 1;67(3):1105-12.

35.

A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis.

Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, Sherr DH.

Biol Chem. 2006 Sep;387(9):1175-87. Review.

PMID:
16972784
38.

Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.

Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE.

Cancer Res. 2005 Dec 15;65(24):11375-83.

39.

Notch1 augments NF-kappaB activity by facilitating its nuclear retention.

Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, Sonenshein GE, Osborne BA.

EMBO J. 2006 Jan 11;25(1):129-38. Epub 2005 Dec 1.

40.

Green tea polyphenol epigallocatechin-3 gallate (EGCG) affects gene expression of breast cancer cells transformed by the carcinogen 7,12-dimethylbenz[a]anthracene.

Guo S, Yang S, Taylor C, Sonenshein GE.

J Nutr. 2005 Dec;135(12 Suppl):2978S-2986S. doi: 10.1093/jn/135.12.2978S.

PMID:
16317158
41.

Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors.

Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff RD, Xiao ZX, Sherr DH, Seldin DC.

Toxicol Pathol. 2005;33(6):726-37.

PMID:
16263698
42.

RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland.

Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, Landesman-Bollag E, Seldin DC, Sonenshein GE.

Mol Cell Biol. 2005 Nov;25(22):10136-47.

43.

Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors.

Murray SA, Yang S, Demicco E, Ying H, Sherr DH, Hafer LJ, Rogers AE, Sonenshein GE, Xiao ZX.

J Cell Biochem. 2005 Aug 1;95(5):875-84.

PMID:
15844214
44.

B-Myb represses elastin gene expression in aortic smooth muscle cells.

Hofmann CS, Wang X, Sullivan CP, Toselli P, Stone PJ, McLean SE, Mecham RP, Schreiber BM, Sonenshein GE.

J Biol Chem. 2005 Mar 4;280(9):7694-701. Epub 2004 Dec 21.

47.

The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells.

Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein GE, Trackman PC.

J Biol Chem. 2004 Sep 24;279(39):40593-600. Epub 2004 Jul 23.

48.

B-Myb represses vascular smooth muscle cell collagen gene expression and inhibits neointima formation after arterial injury.

Hofmann CS, Sullivan CP, Jiang HY, Stone PJ, Toselli P, Reis ED, Chereshnev I, Schreiber BM, Sonenshein GE.

Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1608-13. Epub 2004 Jul 15.

PMID:
15256398
49.
50.

Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes.

Cavin LG, Romieu-Mourez R, Panta GR, Sun J, Factor VM, Thorgeirsson SS, Sonenshein GE, Arsura M.

Hepatology. 2003 Dec;38(6):1540-51.

PMID:
14647065

Supplemental Content

Loading ...
Support Center